Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Ovarian Tissue Cryopreservation for Fertility Preservation

for
Cancer, Autoimmune Diseases
Location: Pittsburgh PA
Sponsor: University of Pittsburgh

Sex: Female

Age: 0 - 39

Code: NCT05875155

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

for
Tumor, Subjects
Location: San Antonio TX
Sponsor: Huabo Biopharm Co., Ltd.

Sex: All

Age: 18+

Code: NCT04678908

Phase 1, Recruiting

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

for
Advanced Solid Tumors
Location: Miami Beach FL, St. Petersburg FL, New Orleans LA
Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Sex: All

Age: 18+

Code: NCT05277168

Phase 1, Phase 2, Recruiting

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)

for
Breast Cancer, Oligoprogressive, Head and Neck Cancer, Sarcoma,
Location: Sacramento CA
Sponsor: University of California, Davis

Sex: All

Age: 18+

Code: NCT06103669

Recruiting

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

for
Cancer Diagnosis
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 45+

Code: NCT06523868

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

for
Advanced/Metastatic Solid Tumors, Colorectal Cancer,
Location: Boston MA, New York NY, Philadelphia PA, Syracuse NY,
Sponsor: Genmab

Sex: All

Age: 18+

Code: NCT03526835

Phase 1, Phase 2, Recruiting

Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Nashville TN
Sponsor: MetaboMed Inc

Sex: All

Age: 18+

Code: NCT04990739

Phase 1, Recruiting

Prospective Urban Rural Epidemiology Study

for
Cardiovascular Diseases, Risk Factor, Cardiovascular,
Location: Quebec City, Ottawa, Hamilton, Vancouver
Sponsor: Population Health Research Institute

Sex: All

Age: 35 - 70

Code: NCT03225586

Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

for
Advanced Solid Tumors, HNSCC, SCLC, NSCLC,
Location: Boston MA, New York NY, New Haven CT, Miami FL, Toronto,
Sponsor: Tubulis GmbH

Sex: All

Age: 18+

Code: NCT06657222

Phase 1, Phase 2, Recruiting

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

for
Solid Tumor
Location: Grand Rapids MI, Scottsdale AZ
Sponsor: Qualigen Theraputics, Inc.

Sex: All

Age: 18+

Code: NCT06086522

Phase 1, Recruiting

Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients

for
Advanced Cancers
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 0+

Code: NCT02160366

Recruiting

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

for
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma,
Location: Miami FL, Huntersville NC, Grand Rapids MI,
Sponsor: Aulos Bioscience, Inc.

Sex: All

Age: 18+

Code: NCT05267626

Phase 1, Phase 2, Recruiting

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

for
Prostate Cancer Recurrent, Solid Tumor, Adult
Location: Charleston SC
Sponsor: Medical University of South Carolina

Sex: All

Age: 18+

Code: NCT05036226

Phase 1, Phase 2, Recruiting

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

for
Melanoma Stage IV, Solid Tumor
Location: Boston MA, New York NY, Richmond VA, Cincinnati OH,
Sponsor: Georgiamune Inc

Sex: All

Age: 18+

Code: NCT06425926

Phase 1, Phase 2, Recruiting

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

for
Advanced Solid Malignancies
Location: New Brunswick NJ, Richmond VA, Sarasota FL,
Sponsor: Georgiamune Inc

Sex: All

Age: 18+

Code: NCT06028074

Phase 1, Phase 2, Recruiting

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

for
NSCLC (Non-small Cell Lung Cancer), Solid Tumor
Location: Fairfax VA
Sponsor: Yuhan Corporation

Sex: All

Age: 18+

Code: NCT06616766

Phase 1, Phase 2, Recruiting

UCSD Image-Guided Cognitive-Sparing Radiosurgery for Intracranial Lesions

for
Brain Metastases, Adult, Neurocognitive Function, Cancer,
Location: San Diego CA
Sponsor: Jona Hattangadi-Gluth

Sex: All

Age: 18+

Code: NCT04343157

Phase 2, Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

for
Neoplasms
Location: The Bronx NY, New York NY, East Brunswick NJ,
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06150157

Phase 1, Recruiting

A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

for
Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
Location: Huntersville NC
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Sex: All

Age: 18+

Code: NCT05569057

Phase 1, Recruiting

A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention

for
Solid Tumor, Adult
Location: Chico CA
Sponsor: University of California, Davis

Sex: All

Age: 18+

Code: NCT06436157

Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial